NCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
Clinical Trials
7 trialsNCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT05618366 2026-04-02
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT05994235 2026-04-02
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06242834 2026-04-01
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn